✦ LIBER ✦

Autologous stem cell transplants in treatment of multiple sclerosis: Where we stand and future prospects

✍ Scribed by Athanasios Fassas

Publisher: Carden Jennings Publishing
Year: 2002
Tongue: English
Weight: 433 KB
Volume: 76
Category: Article
ISSN: 0925-5710
DOI: 10.1007/bf03165250

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcome of autologous periphera

Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population

✍ Juan Xu; Bing-Xin Ji; Li Su; Hui-Qing Dong; Wan-Ling Sun; Sui-Gui Wan; Ya-Ou Liu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 177 KB

Guidelines for autologous blood and marr

Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation

✍ G. Comi; L. Kappos; M. Clanet; G. Ebers; A. Fassas; F. Fazekas; M. Filippi; H.P. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 125 KB

A staged approach with vincristine, adri

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

✍ C. S. Chim; A. K. W. Lie; E. Y. T. Chan; Y. Y. Leung; S. C. W. Cheung; S. Y. T. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 319 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame